Diabetes, TZDs, and Bone: A Review of the Clinical Evidence

Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether P...

Descripción completa

Detalles Bibliográficos
Autor principal: Schwartz, Ann V.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779575/
https://www.ncbi.nlm.nih.gov/pubmed/17259663
http://dx.doi.org/10.1155/PPAR/2006/24502
_version_ 1782131808080494592
author Schwartz, Ann V.
author_facet Schwartz, Ann V.
author_sort Schwartz, Ann V.
collection PubMed
description Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether PPAR-γ activation also impacts bone in humans. In addition, since type 2 diabetes is associated with higher fracture risk, an understanding of the clinical impact of TZDs on bone is needed to guide fracture prevention efforts in this population. This review summarizes current findings regarding type 2 diabetes and increased fracture risk and then considers the available evidence regarding TZD use and bone metabolism in humans.
format Text
id pubmed-1779575
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-17795752007-02-01 Diabetes, TZDs, and Bone: A Review of the Clinical Evidence Schwartz, Ann V. PPAR Res Review Article Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether PPAR-γ activation also impacts bone in humans. In addition, since type 2 diabetes is associated with higher fracture risk, an understanding of the clinical impact of TZDs on bone is needed to guide fracture prevention efforts in this population. This review summarizes current findings regarding type 2 diabetes and increased fracture risk and then considers the available evidence regarding TZD use and bone metabolism in humans. Hindawi Publishing Corporation 2006 2006-09-20 /pmc/articles/PMC1779575/ /pubmed/17259663 http://dx.doi.org/10.1155/PPAR/2006/24502 Text en Copyright © 2006 Ann V. Schwartz. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Schwartz, Ann V.
Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
title Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
title_full Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
title_fullStr Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
title_full_unstemmed Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
title_short Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
title_sort diabetes, tzds, and bone: a review of the clinical evidence
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1779575/
https://www.ncbi.nlm.nih.gov/pubmed/17259663
http://dx.doi.org/10.1155/PPAR/2006/24502
work_keys_str_mv AT schwartzannv diabetestzdsandboneareviewoftheclinicalevidence

Ejemplares similares